Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer’s Disease in APP+PS1 Mice
Open Access
- 3 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e49468
Abstract
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vaccine against Alzheimer’s disease (AD). In preparation of this vaccine, we sensitized the isolated dendritic cells ex vivo with Aβ peptide, and administered these sensitized dendritic cells as a therapeutic agent. This form of cell therapy has had success in preventing and/or slowing the rate of cognitive decline when administered prior to the appearance of Aβ plaques in PDAPP mice, but has not been tested in 2×Tg models. Herein, we test the efficacy and safety of this vaccine in halting and reversing Alzheimer’s pathology in 9-month-old APP+PS1 mice. The results showed that administration of this vaccine elicits a long-lasting antibody titer, which correlated well with a reduction of Aβ burden upon histological analysis. Cognitive function in transgenic responders to the vaccine was rescued to levels similar to those found in non-transgenic mice, indicating that the vaccine is capable of providing therapeutic benefit in APP+PS1 mice when administered after the onset of AD pathology. The vaccine also shows indications of circumventing past safety problems observed in AD immunotherapy, as Th1 pro-inflammatory cytokines were not elevated after long-term vaccine administration. Moreover, microhemorrhaging and T-cell infiltration into the brain are not observed in any of the treated subjects. All in all, this vaccine has many advantages over contemporary vaccines against Alzheimer’s disease, and may lead to a viable treatment for the disease in the future.Keywords
This publication has 63 references indexed in Scilit:
- Modes of Aβ toxicity in Alzheimer’s diseaseCellular and Molecular Life Sciences, 2011
- Epidemiology of Alzheimer diseaseNature Reviews Neurology, 2011
- Immunotherapy for Alzheimer’s diseaseJournal of Internal Medicine, 2010
- Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented IndividualsPLOS ONE, 2009
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- G-CSF rescues the memory impairment of animal models of Alzheimer's diseaseJournal of Experimental Medicine, 2007
- Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Aβ1–6: Toward safer and effective vaccines against Alzheimer’s diseaseBiochemical and Biophysical Research Communications, 2005
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cellsHuman Immunology, 1997